Nav: Home

Mechanism explains breast cancer cell plasticity

January 28, 2019

One of the main obstacles to successfully treating breast cancer is the cells' ability to change in ways that make them resistant to treatment. Understanding the cellular mechanisms that mediate this cancer cell plasticity may lead to improved treatments. Taking a step in that direction, a team led by researchers at Baylor College of Medicine has discovered that breast cancer cells can shift between two forms of the cell surface molecule CD44, CD44s and CD44v. Published in the journal Genes & Development, the study shows that breast cancer cells expressing mainly CD44s have increased metastatic behavior and resistance to therapy, while those expressing CD44v do not associate with these behaviors but do present increased cell proliferation.

"One of the goals of my lab is to better understand the mechanisms that allow breast cancer cells to be remarkably heterogeneous, which is one of the reasons cancer is difficult to treat," said corresponding author Dr. Chonghui Cheng, associate professor at the Lester and Sue Smith Breast Center, of molecular and human genetics and of molecular and cellular biology at Baylor College of Medicine. "In this study, we investigated cancer stem cells, a cell population that has the plasticity to generate cells with different properties, focusing on the cell surface molecule CD44."

CD44 is a well-known marker of cancer stem cells and one that is extensively studied in the Cheng lab. The CD44 gene can produce two different forms of the protein - CD44s and CD44v - via a process called alternative splicing. Cheng and her colleagues investigated whether there was a difference in the two forms of CD44 expressed in human breast cancer cells. They also wanted to know whether the different forms of CD44 contributed differently to the disease.

To answer their questions, Cheng and her colleagues took an unbiased approach. They conducted bioinformatics analyses of breast cancer patient data collected in the Cancer Genome Atlas database.

"Our analyses show that CD44s and CD44v, the two major forms of CD44 generated by alternative splicing, have distinct biological functions in breast cancer," said Cheng, who also is a member of the Dan L Duncan Comprehensive Cancer Center.

"Our findings support that cancer cells can use different forms of CD44 to survive and that they also can switch from one form of CD44 to the other," said Cheng. "Cancer cells expressing high levels of CD44s have properties of cancer stem cells, they tend to be metastatic or recurrent and to survive treatment. But when they switch to CD44v, they have fewer cancer stem cell properties but are engaged in proliferation. Alternative splicing is the mechanism that allows the CD44 proteins to switch."

The researchers envision that by manipulating the levels of the two forms of CD44, it might be possible to change the cancer cell properties in ways that may enhance the cancer's susceptibility to treatment.

"We anticipate that other genes that also undergo alternative splicing could as well contribute to the cells' fate and to the plasticity that generates cancer heterogeneity," Cheng said.
Other contributors to this work include Honghong Zhang, Rhonda L. Brown, Pu Zhao, Sali Liu, Xuan Liu, Yu Deng, Xiaohui Hu, Jing Zhang, Xin D. Gao, Yibin Kang, Arthur M. Mercurio and Hira Lal Goel. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, Northwestern University Feinberg School of Medicine, Princeton University and University of Massachusetts Medical School.

This study was supported by National Institutes of Health grants R01CA182467, R01GM110146, R01CA203439 and T32CA080621, the Brewster Foundation, the Susan G. Komen Foundation and the Cancer Prevention Research Institute of Texas Rising Star Award RR160009.

Baylor College of Medicine

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
One-third of breast cancer patients not getting appropriate breast imaging follow-up exam
An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren't receiving this follow-up exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
Low breast density worsens prognosis in breast cancer
Even though dense breast tissue is a risk factor for breast cancer, very low mammographic breast density is associated with a worse prognosis in breast cancer patients.
Is breast conserving therapy or mastectomy better for early breast cancer?
Young women with early breast cancer face a difficult choice about whether to opt for a mastectomy or breast conserving therapy (BCT).
Breast density and outcomes of supplemental breast cancer screening
In a study appearing in the April 26 issue of JAMA, Elizabeth A.
Full dose radiotherapy to whole breast may not be needed in early breast cancer
Five years after breast-conserving surgery, radiotherapy focused around the tumor bed is as good at preventing recurrence as irradiating the whole breast, with fewer side effects, researchers from the UK have found in the large IMPORT LOW trial.

Related Breast Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".